-
Palisades added 137,768 shares of Travere Therapeutics; Estimated business size of $5.26 million based on quarterly average price.
-
The position represents 1.99% of 13F assets under management (AUM).
-
Travere Therapeutics is not among the fund’s top five holdings after the trade.
-
These 10 stocks could generate the next wave of millionaires ›
According to a Securities and Exchange Commission (SEC) filing dated January 20, 2026, Palisades Investment Partners, LLC reported having initiated a new position in Travere Therapeutics (NASDAQ:TVTX).
The fund purchased 137,768 shares, with an estimated deal value of $5.26 million based on the quarterly average share price. The value of the new stake at the end of the quarter also amounted to $5.26 million, reflecting the company’s share price at the end of the period.
This new position represents 1.99% of Palisades Investment Partners’ $264.72 million in reportable U.S. equity assets as of December 31, 2025.
Top five holdings after the presentation:
-
NASDAQ: STRL: $29.86 million (11.3% of assets under management)
-
New York Stock Exchange: SPXC: $23.04 million (8.7% of assets under management)
-
NASDAQ:WGS: $11.34 million (4.3% of assets under management)
-
NASDAQ: KRYS: $10.54 million (4.0% of assets under management)
-
NASDAQ: MMYT: $9.80 million (3.7% of assets under management)
As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, up 50.89% over the past year and outperforming the S&P 500 by 34.01 percentage points.
|
Metric |
Worth |
|---|---|
|
Price (at market close on January 16, 2026) |
$27.87 |
|
Market capitalization |
$2.46 billion |
|
Revenue (TTM) |
$435.83 million |
|
Net Income (TTM) |
($88.54 million) |
-
Travere Therapeutics generates revenue from marketed therapies for rare diseases, including Chenodal, Cholbam and Thiola/Thiola EC, with additional pipeline assets such as Sparsentan and TVT-058 in clinical development.
-
The company operates a biopharmaceutical business model, focusing on the identification, development and commercialization of treatments for rare and specialized diseases, leveraging proprietary research and strategic collaborations.
-
Travere Therapeutics serves patients with rare metabolic and renal disorders, focusing on high-need indications through partnerships with advocacy organizations and research institutions.
Travere Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of therapies for rare diseases. The company leverages a diversified portfolio of approved products and a portfolio targeting high-need indications, supported by strategic partnerships and clinical research initiatives.
Travere’s focus on rare disease markets positions it to address unmet medical needs and drive growth through targeted innovation and commercialization.